Nexalin Technology, Inc. (NXL)
| Market Cap | 7.25M -70.6% |
| Revenue (ttm) | 275,582 +78.8% |
| Net Income | -8.33M |
| EPS | -0.47 |
| Shares Out | 20.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,321 |
| Open | 0.3480 |
| Previous Close | 0.3440 |
| Day's Range | 0.3480 - 0.3599 |
| 52-Week Range | 0.3302 - 2.0000 |
| Beta | 3.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid... [Read more]
Financial Performance
In 2025, Nexalin Technology's revenue was $301,647, an increase of 78.78% compared to the previous year's $168,721. Losses were -$8.22 million, 8.08% more than in 2024.
Financial StatementsNews
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Publication reports statistically significant improvement in sleep quality following treatment with Nexalin's 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group
Nexalin Technology enters agreements to advance HALO Clarity trial
Nexalin Technology (NXL) entered into agreements to advance its planned pivotal clinical trial evaluating the HALO Clarity device for the treatment of moderate-to-severe insomnia, with patient enrollm...
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designe...
Nexalin Technology advances FDA Alzheimer’s strategy
Nexalin Technology (NXL) announced the completion of a series of high-level meetings in the United States and China focused on advancing the Company’s global clinical strategy for the treatment of
Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the b...
Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).
Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin's differentiated, non-i...
Nexalin Technology price target lowered to $2 from $4 at Maxim
Maxim lowered the firm’s price target on Nexalin Technology (NXL) to $2 from $4 and keeps a Buy rating on the shares. The firm is citing its lower revenue estimates
Nexalin announces continued advancement toward trial evaluating HALO Clarity
Nexalin Technology (NXL) announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin...
Nexalin announces continued advancement toward trial evaluating HALO Clarity
Nexalin Technology (NXL) announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin...
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment
Nexalin ‘commended’ recent Congressional initiative on neurostim research
Nexalin Technology (NXL) “commended” the recent series of bipartisan Congressional initiatives expanding federal focus on deep brain neurostimulation and related neuromodulation research within the U....
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
Nexalin Technology launches AI-designed virtual clinic platform NeuroCare
Nexalin Technology (NXL) announced the launch of its new AI-designed virtual clinic platform, NeuroCare, in collaboration with the University of California, San Diego. This marks the first step in dep...
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for ...
Nexalin Technology highlights research validating neurostimulation technology
Nexalin Technology (NXL) highlighted Nexalin’s peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently...
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the br...
Nexalin Technology announces publication of peer-reviewed study on DIFS
Nexalin Technology (NXL) announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry demonstrating Nexalin’s Deep Intracranial Frequency Stimulation, DIFS, technology produ...
Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the br...
Nexalin Technology completes FDA Q-sub meeting for Gen-2 SYNC neurostimulation
Nexalin Technology (NXL) announced the successful completion of a substantive Q-Submission, Q-Sub, meeting with the U.S. Food and Drug Administration, FDA, regarding its Gen-2 SYNC neurostimulation co...
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program
HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today an...
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The...
Nexalin announces results for 15 mA neurostimulation device
Nexalin Technology (NXL) announced the publication of an independent, peer-reviewed study in The American Journal on Addictions titled “High-intensity transcranial alternating current stimulation for ...
Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today an...
Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel
Nexalin Technology (NXL) announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies, a leading Israeli medical device distributor, to market and sell Nexalin’...